top of page


Highlights from ESMO BREAST 2024: Insights on locally advanced or metastatic HR-positive/HER2-negative breast cancer

The ESMO Breast Cancer 2024 conference held in Berlin, Germany, on May 15th through 17th offered an incredible opportunity to hear the latest research and to discuss the current issues in breast cancer, including future strategies for ensuring better care for patients. It was also a fantastic opportunity for MEDSIR to share two of our trials with the scientific community: LUZERN and an exploratory study of METALLICA. This event is a multidisciplinary meeting with a global scope, involving top scientists in breast cancer research, to share and discuss the latest findings.  

ESMO breast cancer 2024

LUZERN trial: Redefining Outcomes for Patients with BRCA-mutated HR-positive/HER2- advanced breast cancer 


We were excited to share the final results from the LUZERN trial, which is evaluating the efficacy –as determined by the clinical benefit rate– of niraparib in combination with aromatase inhibitors (AIs) in unresectable locally advanced or metastatic HR+/HER2- breast cancer patients harboring either germline BRCA mutations (gBRCAms) or germline BRCA wild-type (gBRCAwt) with homologous recombination deficiency (HRD).  

This multicenter, open-label, two-arm, phase II trial (NCT04240106) enrolled patients from seven medical institutions across Spain between 2020 and 2022. The study demonstrated that the combination of niraparib plus aromatase inhibitors may be an effective treatment with manageable side effects for patients that have aromatase inhibitor resistant HR-positive/HER2-negative advanced breast cancer harboring gBRCAms. The clinical benefit rate was 50%, with a median progression free survival of 6.9 months and a median overall survival of 18.1 months. The most common treatment related side effects were fatigue, nausea, and abnormally low white blood cell counts. The results of the LUZERN study warrant further research on this combination.  


Download the poster here to learn more about the LUZERN clinical trial. We also encourage you to download the lay language summary.

Daniel Alcalá López PhD. presenting the LUZERN trial at ESMO breast 2024

METALLICA sub-study: Promising therapies for enhanced efficacy in HR+/HER2-/PIK3CA-mutated ABC Patients post CDK4/6i treatment


The second study we presented is an exploratory sub-study of our METALLICA trial (NCT04300790), which retrospectively examined the impact that time to progression on the prior CDK4/6i-based regimen had on the efficacy of alpelisib (ALP) plus endocrine therapy (ET) in patients with HR+/HER2-/PIK3CA-mutated advance breast cancer (ABC). 


The study revealed that in patients with prior exposure to CDK4/6i ≥12 months, ALP plus ET had better prognosis outcome in terms of progression-free survival (HR=0.24; 95%CI: 0.09- 0.58, p=0.002) and 1-year overall survival (HR=0.10; 95%CI: 0.01-0.90, p=0.040) compared to patients with a time to progression on previous CDK4/6i therapy <12 months. 


Download the poster here to learn more about the METALLICA clinical trial. We also encourage you to download the lay language summary to better understand our research. 


Dr. Juan José García Mosquera presenting the exploratory study of METALLICA at ESMO breast 2024

We are extremely proud of the work done at ESMO and we would like to especially thank to Daniel Alcalá-López, Data Science Expert at MEDSIR, and Dr. Juan José García Mosquera, Medical Oncologist from Instituto Oncológico Dr. Rosell (IOR) and MEDSIR’s Medical Monitor, for presenting these two studies with the community.  


Finally, we cannot wait to participate in the ESMO Breast Cancer Congress again next year! Please contact us if you want more information about any of the trials we presented and make sure to download the posters!  

MEDSIR team at ESMO Breast 2024

What's next on MEDSIR's agenda?

Finally, as a gold standard event in oncology, the Annual ASCO Meeting is one of the most highly anticipated oncology conferences of the year and we are thrilled to be participating this year with a team onsite! The meeting is a fantastic forum to discuss and debate the current standards of cancer care and work together to determine how to improve upon ongoing issues and controversies. We are excited to announce that, we are presenting twelve studies in poster format and an oral presentation in alliance with Oncoclínicas & Co, the leading oncology group in Brazil and Latin America. Our commitment to science and to our patients at the global level has never been stronger and we are glad of this alliance to promote global research.  




bottom of page